Warning! GuruFocus detected
1 Severe warning sign
with INDP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Indaptus Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45339J1051
Description
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 68.89 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.6 | |||||
| 3-Year EPS without NRI Growth Rate | 5.2 | |||||
| 3-Year FCF Growth Rate | 21.9 | |||||
| 3-Year Book Growth Rate | -57.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.53 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.19 | |||||
| 9-Day RSI | 16.55 | |||||
| 14-Day RSI | 22.33 | |||||
| 3-1 Month Momentum % | -6.82 | |||||
| 6-1 Month Momentum % | -29.31 | |||||
| 12-1 Month Momentum % | -63.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.95 | |||||
| Quick Ratio | 1.95 | |||||
| Cash Ratio | 1.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.3 | |||||
| Shareholder Yield % | -81.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -200.02 | |||||
| ROA % | -151.51 | |||||
| ROIC % | -890.78 | |||||
| 3-Year ROIIC % | -1468.65 | |||||
| ROC (Joel Greenblatt) % | -11967.29 | |||||
| ROCE % | -203.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.4 | |||||
| Price-to-Tangible-Book | 1.39 | |||||
| EV-to-EBIT | -0.07 | |||||
| EV-to-EBITDA | -0.07 | |||||
| EV-to-FCF | -0.09 | |||||
| Price-to-Net-Current-Asset-Value | 1.7 | |||||
| Price-to-Net-Cash | 2.3 | |||||
| Earnings Yield (Greenblatt) % | -1428.57 | |||||
| FCF Yield % | -184.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INDP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Indaptus Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.62 | ||
| Beta | 1.25 | ||
| 3-Year Sharpe Ratio | -0.63 | ||
| 3-Year Sortino Ratio | -0.86 | ||
| Volatility % | 43.92 | ||
| 14-Day RSI | 22.33 | ||
| 14-Day ATR ($) | 0.097028 | ||
| 20-Day SMA ($) | 0.68588 | ||
| 12-1 Month Momentum % | -63.56 | ||
| 52-Week Range ($) | 0.455 - 3.1 | ||
| Shares Outstanding (Mil) | 14.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Indaptus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Indaptus Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Indaptus Therapeutics Inc Frequently Asked Questions
What is Indaptus Therapeutics Inc(INDP)'s stock price today?
The current price of INDP is $0.46. The 52 week high of INDP is $3.10 and 52 week low is $0.46.
When is next earnings date of Indaptus Therapeutics Inc(INDP)?
The next earnings date of Indaptus Therapeutics Inc(INDP) is 2025-05-08 Est..
Does Indaptus Therapeutics Inc(INDP) pay dividends? If so, how much?
Indaptus Therapeutics Inc(INDP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers